Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Terns Pharmaceuticals Inc (NQ: TERN ) 7.550 +0.220 (+3.00%) Streaming Delayed Price Updated: 1:39 PM EDT, Jun 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Terns Pharmaceuticals Inc < Previous 1 2 3 Next > Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) June 03, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences May 30, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day May 17, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates May 13, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Leadership Changes May 08, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 May 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) May 03, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation April 29, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer April 10, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates March 14, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia March 11, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) March 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences February 27, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) February 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer February 07, 2024 Proven Industry Executive Brings More Than 25 Years of Leadership Experience From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) February 02, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) January 03, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit November 29, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer November 27, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates November 14, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023 November 13, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences November 09, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) November 03, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity November 02, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming Investor Conferences October 19, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia October 16, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) October 03, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) September 06, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences September 05, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.